Application and Research Progress of Radiotherapy in Unresectable Hepatocellular Carcinoma
DOI:
https://doi.org/10.54097/cxexwg51Keywords:
Liver Tumor, Hepatocellular Carcinoma, Radiotherapy, Radiotherapy TechniquesAbstract
Unresectable hepatocellular carcinoma (uHCC) accounts for 70%-80% of newly diagnosed hepatocellular carcinoma (HCC) cases, presenting significant clinical challenges in treatment. Conventional therapies such as transarterial chemoembolization (TACE) or systemic approaches (targeted/immunotherapy) have shown limited efficacy, with a 5-year survival rate below 15%. Recent advancements in precision radiotherapy technologies (stereotactic body radiation therapy [SBRT], proton/heavy ion therapy) combined with synergistic exploration of immunotherapy and targeted therapies have transformed radiotherapy from a palliative to a curative modality. This systematic review examines the technological progress, core clinical applications, challenges, and controversies in uHCC radiotherapy over the past five years, while outlining future research directions to inform clinical practice and scientific inquiry.
Downloads
References
[1] Bray, Freddie et al. “Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.” CA: a cancer journal for clinicians vol. 74,3 (2024): 229-263. doi:10.3322/caac.21834.
[2] Forner, Alejandro et al. “Hepatocellular carcinoma.” Lancet (London, England) vol. 391,10127 (2018): 1301-1314. doi:10. 1016/ S0140-6736(18)30010-2.
[3] Finn, Richard S et al. “Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.” The New England journal of medicine vol. 382,20 (2020): 1894-1905. doi:10. 1056/ NEJMoa1915745.
[4] Kudo, Masatoshi et al. “Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.” Lancet (London, England) vol. 391,10126 (2018): 1163-1173. doi:10. 1016/ S0140-6736(18)30207-1.
[5] Bae, Sun Hyun et al. “Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Meta-Analysis and International Stereotactic Radiosurgery Society Practice Guidelines.” International journal of radiation oncology, biology, physics vol. 118,2 (2024): 337-351. doi: 10.1016/j.ijrobp.2023.08.015.
[6] Ogino, Ryo et al. “A dose-volume intercomparison of volumetric-modulated arc therapy, 3D static conformal, and rotational conformal techniques for portal vein tumor thrombus in hepatocellular carcinoma.” Journal of radiation research vol. 54,4 (2013): 697-705. doi:10.1093/jrr/rrs139.
[7] Kim, Kangpyo et al. “A phase II trial of hypofractionated high-dose proton beam therapy for unresectable liver metastases.” Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology vol. 176 (2022): 9-16. doi:10.1016/j.radonc.2022.09.003.
[8] Benson, R et al. “Radiation induced liver disease: A clinical update.” Journal of the Egyptian National Cancer Institute vol. 28,1 (2016): 7-11. doi:10.1016/j.jnci.2015.08.001.
[9] Kang, Jingbo et al. “Stereotactic body radiotherapy combined with transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombosis.” Molecular and clinical oncology vol. 2,1 (2014): 43-50. doi:10.3892/ mco. 2013. 196.
[10] Li, Han et al. “External radiotherapy combined with sorafenib has better efficacy in unresectable hepatocellular carcinoma: a systematic review and meta-analysis.” Clinical and experimental medicine vol. 23,5 (2023): 1537-1549. doi:10. 1007/ s10238-022-00972-4.
[11] Higby, Christine et al. “Volumetric-modulated arc therapy (VMAT) versus 3D-conformal radiation therapy in supra-diaphragmatic Hodgkin's Lymphoma with mediastinal involvement: A dosimetric comparison.” Journal of the Egyptian National Cancer Institute vol. 28,3 (2016): 163-8. doi: 10.1016/j.jnci.2016.04.007.
[12] Di Federico, Alessandro et al. “Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials.” Expert opinion on investigational drugs vol. 31,4 (2022): 361-369. doi: 10.1080/13543784.2022.2009455.
[13] Kim, Yeon Joo et al. “Combined transarterial chemoembolization and radiotherapy as a first-line treatment for hepatocellular carcinoma with macroscopic vascular invasion: Necessity to subclassify Barcelona Clinic Liver Cancer stage C.” Radiotherapy and oncology: journal of the European Society for Therapeutic Radiology and Oncology vol. 141 (2019): 95-100. doi:10.1016/j.radonc.2019.08.009.
[14] Du, Shi-Suo et al. “Radiation Therapy Promotes Hepatocellular Carcinoma Immune Cloaking via PD-L1 Upregulation Induced by cGAS-STING Activation.” International journal of radiation oncology, biology, physics vol. 112,5 (2022): 1243-1255. doi:10.1016/j.ijrobp.2021.12.162.
[15] Shen, Jie et al. “Phase I clinical study of personalized peptide vaccination combined with radiotherapy for advanced hepatocellular carcinoma.” World journal of gastroenterology vol. 23,29 (2017): 5395-5404. doi:10.3748/wjg. v23.i29.5395.
[16] Ricke, Jens et al. “Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma.” Journal of hepatology vol. 71,6 (2019): 1164-1174. doi: 10.1016/j.jhep.2019.08.006.
[17] Xin Xia, Xu Xin, Zhai Yirui, et al. Progress in Radiotherapy for Hepatocellular Carcinoma with Portal Vein Thrombosis [J]. Hepatocellular Carcinoma Electronic Journal, 2023,10(03):76-82. DOI:CNKI:SUN:GADZ.0.2023-03-010.
[18] Li Jiaxiang, Yan Mingji, Zhang Nianhua, et al. The clinical efficacy and tumor marker effects of TOMO SBRT combined with targeted immunotherapy in patients with unresectable hepatocellular carcinoma [J]. Imaging Science & Photochemistry, 2024,42(06):685-693.DOI:CNKI: SUN: GKGH. 0.2024-06-020.
[19] Chen Tingting, Yang Yanling, Han Haonan, et al. Advances in radiotherapy for widespread small cell lung cancer in the era of immunotherapy [J]. China Journal of Lung Cancer, 2025,28(05): 353-362.DOI:CNKI:SUN:FAIZ.0.2025-05-004.
[20] Han Youxi, Ma Ronghui, Ai Xiuqing, et al. The Impact of EGFR-TKI on the Remote Effect of Radiotherapy in Lung Cancer Mice Through the cGAS-STING Signaling Pathway [J]. Shandong Medicine, 2024,64(31):45-50.DOI:CNKI: SUN: SDYY. 0.2024-31-009.
[21] Wang, Quan et al. “Stereotactic Body Radiotherapy Combined With Lenvatinib With or Without PD-1 Inhibitors as Initial Treatment for Unresectable Hepatocellular Carcinoma.” International journal of radiation oncology, biology, physics vol. 120,5 (2024): 1363-1376. doi:10. 1016/j. ijrobp. 2024. 03.035.
[22] Galluzzi, Lorenzo et al. “Activating autophagy to potentiate immunogenic chemotherapy and radiation therapy.” Nature reviews. Clinical oncology vol. 14,4 (2017): 247-258. doi: 10. 1038/ nrclinonc.2016.183.
[23] Li, Jian-Xu et al. “Combining stereotactic body radiotherapy with camrelizumab for unresectable hepatocellular carcinoma: a single-arm trial.” Hepatology international vol. 16,5 (2022): 1179-1187. doi:10.1007/s12072-022-10396-7.
[24] Liu, Yuwei et al. “Efficacy and Safety of PD-1/PD-L1 Inhibitors in Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.” Advances in therapy vol. 40,2 (2023): 521-549. doi:10.1007/s12325-022-02371-3.
[25] Sun, Ze-Yu et al. “Structural insight into CD20/CD3-bispecific antibodies by molecular modeling.” Computers in biology and medicine vol. 185 (2025): 109497. doi:10.1016/j. compbiomed. 2024. 109497.
[26] Singh, Parneet et al. “Diagnostic Performance of FAPI PET/CT vs. 18F-FDG PET/CT in Evaluation of Liver Tumors: A Systematic Review and Meta-analysis.” Molecular imaging and radionuclide therapy vol. 33,2 (2024): 77-89. doi:10.4274/ mirt. galenos.2024.99705.
[27] Hueper, Katja et al. “Assessment of liver ischemia reperfusion injury in mice using hepatic T2 mapping: Comparison with histopathology.” Journal of magnetic resonance imaging: JMRI vol. 48,6 (2018): 1586-1594. doi:10.1002/jmri.26057.
[28] Jun, Baek Gyu et al. “Clinical significance of radiation-induced liver disease after stereotactic body radiation therapy for hepatocellular carcinoma.” The Korean journal of internal medicine vol. 33,6 (2018): 1093-1102. doi:10.3904/kjim. 2016. 412.
[29] Jung, Jinhong et al. “Radiation-induced liver disease after stereotactic body radiotherapy for small hepatocellular carcinoma: clinical and dose-volumetric parameters.” Radiation oncology (London, England) vol. 8 249. 27 Oct. 2013, doi:10.1186/1748-717X-8-249.
[30] Pezeshki, Parmida Sadat, and Reza Ghalehtaki. “The clinical application of ctDNA to predict response to neoadjuvant chemoradiotherapy in patients with locally-advanced rectal cancer.” Biomarker research vol. 11,1 81. 19 Sep. 2023, doi: 10. 1186/s40364-023-00521-5.
[31] Xu, Jieyu et al. “Downregulation of Nitric Oxide Collaborated with Radiotherapy to Promote Anti-Tumor Immune Response via Inducing CD8+ T Cell Infiltration.” International journal of biological sciences vol. 16,9 1563-1574. 5 Mar. 2020, doi:10. 7150/ ijbs.41653.
[32] Khan, Ruby et al. “Comprehensive Bioinformatic Investigation of TP53 Dysregulation in Diverse Cancer Landscapes.” Genes vol. 15,5 577. 30 Apr. 2024, doi:10. 3390/genes15050577.
Downloads
Published
Issue
Section
License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

